Aurinia Pharmaceuticals Inc (STU:IKAP) Stock Price, Trades & News

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Financial Strength

9/10

Name	Current	Vs Industry
Cash-To-Debt	6.91
Equity-to-Asset	0.78
Debt-to-Equity	0.1
Debt-to-EBITDA	0.35
Interest Coverage	36.71
Piotroski F-Score	8/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	7.68	Distress Grey Safe
Beneish M-Score	9.42	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

9/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	29.3
	3-Year Book Growth Rate	15.5
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	20.98
	Future 3-5Y Total Revenue Growth Rate Estimate	16.49

Momentum Rank

9/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	50.97
	9-Day RSI	49.15
	14-Day RSI	47.9
	3-1 Month Momentum %	1.32
	6-1 Month Momentum %	14.73
	12-1 Month Momentum %	42.69

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	5.42
	Quick Ratio	4.97
	Cash Ratio	4.44
	Days Inventory	555.46
	Days Sales Outstanding	47.47
	Days Payable	32.17

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	2.4
	Shareholder Yield %	4.56

Profitability Rank

4/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	90.36
	Operating Margin %	48.39
	Net Margin %	100.84
	EBITDA Margin %	59.02
	FCF Margin %	56.18
	OCF Margin %	56.24
	ROE %	63.72
	ROA %	47.62
	ROIC %	67.82
	3-Year ROIIC %	90.03
	ROC (Joel Greenblatt) %	157.01
	ROCE %	28.72
	Years of Profitability over Past 10-Year	2
	Moat Score	4
	Tariff Resilience Score	8

GF Value Rank

7/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	6.75
	Forward PE Ratio	16.05
	PE Ratio without NRI	6.75
	Price-to-Owner-Earnings	5.85
	PS Ratio	6.76
	PB Ratio	3.34
	Price-to-Tangible-Book	3.36
	Price-to-Free-Cash-Flow	12.01
	Price-to-Operating-Cash-Flow	11.99
	EV-to-EBIT	10.2
	EV-to-EBITDA	9.13
	EV-to-Revenue	5.39
	EV-to-Forward-Revenue	5.05
	EV-to-FCF	9.58
	Price-to-GF-Value	1.06
	Price-to-Projected-FCF	5.2
	Price-to-Graham-Number	1
	Price-to-Net-Current-Asset-Value	5.64
	Price-to-Net-Cash	7.73
	Earnings Yield (Greenblatt) %	9.8
	FCF Yield %	8.51

Financials (Next Earnings Date:2026-11-04 Est.)

Annual Quarterly TTM

STU:IKAP's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Aurinia Pharmaceuticals Inc Executives

Details

GF Value™: €12.63

STU:IKAP

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 1 Severe warning sign with IKAP. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	267.9
	EPS (TTM) (€)	1.962
	Beta	0.9788
	3-Year Sharpe Ratio	0.26
	3-Year Sortino Ratio	0.4
	Volatility %	50.88
	14-Day RSI	47.9
	14-Day ATR (€)	0.446913
	20-Day SMA (€)	13.3605
	12-1 Month Momentum %	42.69
	52-Week Range (€)	9.268 - 16.77
	Shares Outstanding (Mil)	133.05

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	8
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Aurinia Pharmaceuticals Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Aurinia Pharmaceuticals Inc Stock Events

Financials Calendars

Event	Date	Price (€)
Third quarter earnings conference call for 2026	2026-11-04 08:30	In 84 days
Third quarter earnings results for 2026	2026-11-04	In 83 days
Second quarter earnings conference call for 2026	2026-08-11 08:30	13.39 (-1.51%)
Second quarter earnings results for 2026	2026-08-06	13.11 (+1.86%)
General meeting for 2026	2026-06-03 12:00	13.14 (+1.27%)
First quarter earnings conference call for 2026	2026-05-07	13.78 (+1.55%)
First quarter earnings results for 2026	2026-05-07	13.78 (+1.55%)
Fourth quarter earnings conference call for 2025	2026-02-26 08:30	12.16 (-0.65%)
Annual report for 2025	2026-02-26	12.16 (-0.65%)
Fourth quarter earnings results for 2025	2026-02-26	12.16 (-0.65%)

Show

Entries

Aurinia Pharmaceuticals Inc Frequently Asked Questions

What is Aurinia Pharmaceuticals Inc(STU:IKAP)'s stock price today?

The current price of STU:IKAP is €13.37. The 52 week high of STU:IKAP is €16.77 and 52 week low is €9.27.

When is next earnings date of Aurinia Pharmaceuticals Inc(STU:IKAP)?

The next earnings date of Aurinia Pharmaceuticals Inc(STU:IKAP) is 2026-11-04 Est..

Does Aurinia Pharmaceuticals Inc(STU:IKAP) pay dividends? If so, how much?

Aurinia Pharmaceuticals Inc(STU:IKAP) does not pay dividend.

Press Release

	Subject	Date
	Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress	2026-08-06
	Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis	2026-07-06
	LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death	2026-06-04
	Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right	2026-03-30
	Aurinia Announces Management Transition	2026-03-23
	Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress	2026-02-26
	Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026	2026-02-19
	Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress	2025-11-04
	Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025	2025-11-03
	Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025	2025-10-15

10/Page

Articles on Aurinia Pharmaceuticals Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.